ASBP · Aspire Biopharma Holdings, Inc.
One customer — 15% of revenue (the six months ended June 30, 2026)
“One customer accounted for approximately 15% of the Company’s total revenues during the six months ended June 30, 2026.”
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jan 16, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jan 16, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ASBP
this stock
Aspire Biopharma Holdings, Inc.
|
$12.44M | — | — | — | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +20.5% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.22B | +7.2% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$64.25B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jan 16, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ASBP | +4.2% | +14.8% | +809.7% | -1.2% | — |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +4.1% | +15.2% | +794.6% | -1.6% | — |